Michelle Crouthamel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michelle Crouthamel has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Luis Garcia-Gancedo
Affiliation GSK, Stevenage, Hertfordshire, United Kingdom
3 shared publications Darryl Badley
AbbVie, North Chicago, USA
2 shared publications- Earl Ray Dorsey
Center for Health + Technology, University of Rochester, Rochester, NY, USA
2 shared publications - Emilia Quattrocchi
Kyowa Kirin Pharmaceutical Development Ltd Marlow UK
2 shared publications Jie Shen
AbbVie, North Chicago, USA
2 shared publications- Joshua Cosman
AbbVie Pharmaceuticals, North Chicago, USA
2 shared publications
Latest Publications
- Open Access
Quantifying Nocturnal Scratch in Atopic Dermatitis: A Machine Learning Approach Using Digital Wrist Actigraphy
Nocturnal scratching substantially impairs the quality of life in individuals with skin conditions such as atopic dermatitis (AD). Current clinical measurements of scratch rely on patient-reported outcomes (PROs) on itch over the last 24 h. Such measurements lack objectivity and sensitivity. Digital health technologies (DHTs), such as wearable sensors, have been widely used to capture behaviors in clinical and real-world settings. In this work, we develop and validate a machine learning algorithm using wrist-wearing actigraphy that could objectively quantify nocturnal scratching events, therefore facilitating accurate assessment of disease progression, treatment effectiveness, and overall quality of life in AD patients. A total of seven subjects were enrolled in a study to generate data overnight in an inpatient setting. Several machine learning models were developed, and their performance was compared. Results demonstrated that the best-performing model achieved the F1 score of 0.45 on the test set, accompanied by a precision of 0.44 and a recall of 0.46. Upon satisfactory performance with an expanded subject pool, our automatic scratch detection algorithm holds the potential for objectively assessing sleep quality and disease state in AD patients. This advancement promises to inform and refine therapeutic strategies for individuals with AD.
Open AccessQuantifying Nocturnal Scratch in Atopic Dermatitis: A Machine Learning Approach Using Digital Wrist Actigraphy
Nocturnal scratching substantially impairs the quality of life in individuals with skin conditions such as atopic dermatitis (AD). Current clinical measurements of scratch rely on patient-reported outcomes (PROs) on itch over the last 24 h. Such measurements lack objectivity and sensitivity. Digital health technologies (DHTs), such as wearable sensors, have been widely used to capture behaviors in clinical and real-world settings. In this work, we develop and validate a machine learning algorithm using wrist-wearing actigraphy that could objectively quantify nocturnal scratching events, therefore facilitating accurate assessment of disease progression, treatment effectiveness, and overall quality of life in AD patients. A total of seven subjects were enrolled in a study to generate data overnight in an inpatient setting. Several machine learning models were developed, and their performance was compared. Results demonstrated that the best-performing model achieved the F1 score of 0.45 on the test set, accompanied by a precision of 0.44 and a recall of 0.46. Upon satisfactory performance with an expanded subject pool, our automatic scratch detection algorithm holds the potential for objectively assessing sleep quality and disease state in AD patients. This advancement promises to inform and refine therapeutic strategies for individuals with AD.
- Open Access
- 15 March 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-9
Improved measurement of disease progression in people living with early Parkinson’s disease using digital health technologies
Background: Digital health technologies show promise for improving the measurement of Parkinson’s disease in clinical research and trials. However, it is not clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches. Methods: To this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and evaluate the sensitivity of digital measures to 1-year longitudinal progression using data from the WATCH-PD study, a multicenter, observational digital assessment study in participants with early, untreated Parkinson’s disease. In total, 82 early, untreated Parkinson’s disease participants and 50 age-matched controls were recruited and took part in a variety of motor tasks over the course of a 12-month period while wearing body-worn inertial sensors. We establish clinical validity of sensor-based digital measures by investigating convergent validity with appropriate clinical constructs, known groups validity by distinguishing patients from healthy volunteers, and test-retest reliability by comparing measurements between visits. Results: We demonstrate clinical validity of the digital measures, and importantly, superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs. Conclusions: Our results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.
- 15 March 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-9
Open AccessImproved measurement of disease progression in people living with early Parkinson’s disease using digital health technologies
Background: Digital health technologies show promise for improving the measurement of Parkinson’s disease in clinical research and trials. However, it is not clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches. Methods: To this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and evaluate the sensitivity of digital measures to 1-year longitudinal progression using data from the WATCH-PD study, a multicenter, observational digital assessment study in participants with early, untreated Parkinson’s disease. In total, 82 early, untreated Parkinson’s disease participants and 50 age-matched controls were recruited and took part in a variety of motor tasks over the course of a 12-month period while wearing body-worn inertial sensors. We establish clinical validity of sensor-based digital measures by investigating convergent validity with appropriate clinical constructs, known groups validity by distinguishing patients from healthy volunteers, and test-retest reliability by comparing measurements between visits. Results: We demonstrate clinical validity of the digital measures, and importantly, superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs. Conclusions: Our results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.
- Open Access
- 26 September 2023
- Published by Springer Nature in Research Square
Enhanced sensitivity to disease progression using digital health technologies in early Parkinson’s disease
Digital health technologies show promise for improving the measurement of Parkinson’s disease in clinical research and trials. However, it currently isn’t clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches. To this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and establish clinical validity by investigating convergent validity with appropriate clinical constructs, known groups validity, and test-retest reliability. Importantly, we demonstrate superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs. Our results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.
- 26 September 2023
- Published by Springer Nature in Research Square
Open AccessEnhanced sensitivity to disease progression using digital health technologies in early Parkinson’s disease
Digital health technologies show promise for improving the measurement of Parkinson’s disease in clinical research and trials. However, it currently isn’t clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches. To this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and establish clinical validity by investigating convergent validity with appropriate clinical constructs, known groups validity, and test-retest reliability. Importantly, we demonstrate superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs. Our results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.
- Open Access
- 2 September 2021
- Published by S. Karger AG in Digital Biomarkers
- Vol. 5 (3) , 191-205
Developing a Novel Measurement of Sleep in Rheumatoid Arthritis: Study Proposal for Approach and Considerations
The development of novel digital endpoints (NDEs) using digital health technologies (DHTs) may provide opportunities to transform drug development. It requires a multidisciplinary, multi-study approach with strategic planning and a regulatory-guided pathway to achieve regulatory and clinical acceptance. Many NDEs have been explored; however, success has been limited. To advance industry use of NDEs to support drug development, we outline a theoretical, methodological study as a use-case proposal to describe the process and considerations when developing and obtaining regulatory acceptance for an NDE to assess sleep in patients with rheumatoid arthritis (RA). RA patients often suffer joint pain, fatigue, and sleep disturbances (SDs). Although many researchers have investigated the mobility of joint functions using wearable technologies, the research of SD in RA has been limited due to the availability of suitable technologies. We proposed measuring the improvement of sleep as the novel endpoint for an anti-TNF therapy and described the meaningfulness of the measure, considerations of tool selection, and the design of clinical validation. The recommendations from the FDA patient-focused drug development guidance, the Clinical Trials Transformation Initiative (CTTI) pathway for developing novel endpoints from DHTs, and the V3 framework developed by the Digital Medicine Society (DiMe) have been incorporated in the proposal. Regulatory strategy and engagement pathways are also discussed.
- 2 September 2021
- Published by S. Karger AG in Digital Biomarkers
- Vol. 5 (3) , 191-205
Open AccessDeveloping a Novel Measurement of Sleep in Rheumatoid Arthritis: Study Proposal for Approach and Considerations
The development of novel digital endpoints (NDEs) using digital health technologies (DHTs) may provide opportunities to transform drug development. It requires a multidisciplinary, multi-study approach with strategic planning and a regulatory-guided pathway to achieve regulatory and clinical acceptance. Many NDEs have been explored; however, success has been limited. To advance industry use of NDEs to support drug development, we outline a theoretical, methodological study as a use-case proposal to describe the process and considerations when developing and obtaining regulatory acceptance for an NDE to assess sleep in patients with rheumatoid arthritis (RA). RA patients often suffer joint pain, fatigue, and sleep disturbances (SDs). Although many researchers have investigated the mobility of joint functions using wearable technologies, the research of SD in RA has been limited due to the availability of suitable technologies. We proposed measuring the improvement of sleep as the novel endpoint for an anti-TNF therapy and described the meaningfulness of the measure, considerations of tool selection, and the design of clinical validation. The recommendations from the FDA patient-focused drug development guidance, the Clinical Trials Transformation Initiative (CTTI) pathway for developing novel endpoints from DHTs, and the V3 framework developed by the Digital Medicine Society (DiMe) have been incorporated in the proposal. Regulatory strategy and engagement pathways are also discussed.
- Open Access
- 13 September 2018
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 6 (9) , e177
Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Using Smartphones to enroll, consent and gather patient-reported data has potential to enhance our understanding of disease burden and quantify physiological impact in the real-world. It may also be possible to harness integral Smartphone sensors to facilitate remote collection of clinically relevant data. Objective: The PAtient Rheumatoid Arthritis Data from the REal World (PARADE) observational study was conducted using a customized ResearchKit application (app) with a ‘bring your own device’ approach. The objective was to assess the feasibility of using an entirely digital approach (social media and Smartphone app) to conduct a real-world observational study of patients with rheumatoid arthritis (RA). Methods: The PARADE app, designed to guide patients through a series of tasks, was publicized via social media platforms and made available for patients in the USA to download from the iPhone App Store, as a means of patient recruitment. Patient-reported data, for example, medical history, RA-related medications (past and present), and a range of patient-reported outcome measures were collected. In addition, a joint pain map and a novel objective assessment of wrist range of motion (ROM), measured by the Smartphone embedded gyroscope and accelerometer, were included in the assessment. Results: Within 1 month of recruitment via social media campaigns, 399 participants self-enrolled, self-consented and provided complete demographic data. Joint pain was the most frequently reported RA symptom to bother study participants (344/393 [87.5%]). Severe patient-reported wrist pain appeared to be inversely linked with the range of wrist movement measured objectively by the app. At study entry, 292/399 participants (73%) indicated a preference for participating in a mobile app-based study. The number of participants in the study declined to 45/399 (11.3%) at week 12. Conclusions: Despite the declining number of participants over time, the combination of social media and Smartphone app with sensor integration was a feasible and cost-effective approach for the collection of patient-reported data in RA. Integral sensors within Smartphones can be harnessed to provide novel endpoints and the novel wrist ROM test warrants further clinical validation.
- 13 September 2018
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 6 (9) , e177
Open AccessUsing a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Using Smartphones to enroll, consent and gather patient-reported data has potential to enhance our understanding of disease burden and quantify physiological impact in the real-world. It may also be possible to harness integral Smartphone sensors to facilitate remote collection of clinically relevant data. Objective: The PAtient Rheumatoid Arthritis Data from the REal World (PARADE) observational study was conducted using a customized ResearchKit application (app) with a ‘bring your own device’ approach. The objective was to assess the feasibility of using an entirely digital approach (social media and Smartphone app) to conduct a real-world observational study of patients with rheumatoid arthritis (RA). Methods: The PARADE app, designed to guide patients through a series of tasks, was publicized via social media platforms and made available for patients in the USA to download from the iPhone App Store, as a means of patient recruitment. Patient-reported data, for example, medical history, RA-related medications (past and present), and a range of patient-reported outcome measures were collected. In addition, a joint pain map and a novel objective assessment of wrist range of motion (ROM), measured by the Smartphone embedded gyroscope and accelerometer, were included in the assessment. Results: Within 1 month of recruitment via social media campaigns, 399 participants self-enrolled, self-consented and provided complete demographic data. Joint pain was the most frequently reported RA symptom to bother study participants (344/393 [87.5%]). Severe patient-reported wrist pain appeared to be inversely linked with the range of wrist movement measured objectively by the app. At study entry, 292/399 participants (73%) indicated a preference for participating in a mobile app-based study. The number of participants in the study declined to 45/399 (11.3%) at week 12. Conclusions: Despite the declining number of participants over time, the combination of social media and Smartphone app with sensor integration was a feasible and cost-effective approach for the collection of patient-reported data in RA. Integral sensors within Smartphones can be harnessed to provide novel endpoints and the novel wrist ROM test warrants further clinical validation.
- Open Access
- 14 December 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study (Preprint)
BACKGROUND Using smartphones to enroll, obtain consent, and gather self-reported data from patients has the potential to enhance our understanding of disease burden and quantify physiological impact in the real world. It may also be possible to harness integral smartphone sensors to facilitate remote collection of clinically relevant data. OBJECTIVE We conducted the Patient Rheumatoid Arthritis Data From the Real World (PARADE) observational study using a customized ResearchKit app with a bring-your-own-device approach. Our objective was to assess the feasibility of using an entirely digital approach (social media and smartphone app) to conduct a real-world observational study of patients with rheumatoid arthritis. METHODS We conducted this observational study using a customized ResearchKit app with a bring-your-own-device approach. To recruit patients, the PARADE app, designed to guide patients through a series of tasks, was publicized via social media platforms and made available for patients in the United States to download from the Apple App Store. We collected patient-reported data, such as medical history, rheumatoid arthritis-related medications (past and present), and a range of patient-reported outcome measures. We included in the assessment a joint-pain map and a novel objective assessment of wrist range of movement, measured by the smartphone-embedded gyroscope and accelerometer. RESULTS Within 1 month of recruitment via social media campaigns, 399 participants self-enrolled, self-consented, and provided complete demographic data. Joint pain was the most frequently reported rheumatoid arthritis symptom to bother study participants (344/393, 87.5%). Severe patient-reported wrist pain appeared to be inversely linked with the range of wrist movement measured objectively by the app. At study entry, 292 of 399 participants (73.2%) indicated a preference for participating in a mobile app–based study. The number of participants in the study declined to 45 of 399 (11.3%) at week 12. CONCLUSIONS Despite the declining number of participants over time, the combination of social media and smartphone app with sensor integration was a feasible and cost-effective approach for the collection of patient-reported data in rheumatoid arthritis. Integral sensors within smartphones can be harnessed to provide novel end points, and the novel wrist range of movement test warrants further clinical validation.
- 14 December 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUsing a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study (Preprint)
BACKGROUND Using smartphones to enroll, obtain consent, and gather self-reported data from patients has the potential to enhance our understanding of disease burden and quantify physiological impact in the real world. It may also be possible to harness integral smartphone sensors to facilitate remote collection of clinically relevant data. OBJECTIVE We conducted the Patient Rheumatoid Arthritis Data From the Real World (PARADE) observational study using a customized ResearchKit app with a bring-your-own-device approach. Our objective was to assess the feasibility of using an entirely digital approach (social media and smartphone app) to conduct a real-world observational study of patients with rheumatoid arthritis. METHODS We conducted this observational study using a customized ResearchKit app with a bring-your-own-device approach. To recruit patients, the PARADE app, designed to guide patients through a series of tasks, was publicized via social media platforms and made available for patients in the United States to download from the Apple App Store. We collected patient-reported data, such as medical history, rheumatoid arthritis-related medications (past and present), and a range of patient-reported outcome measures. We included in the assessment a joint-pain map and a novel objective assessment of wrist range of movement, measured by the smartphone-embedded gyroscope and accelerometer. RESULTS Within 1 month of recruitment via social media campaigns, 399 participants self-enrolled, self-consented, and provided complete demographic data. Joint pain was the most frequently reported rheumatoid arthritis symptom to bother study participants (344/393, 87.5%). Severe patient-reported wrist pain appeared to be inversely linked with the range of wrist movement measured objectively by the app. At study entry, 292 of 399 participants (73.2%) indicated a preference for participating in a mobile app–based study. The number of participants in the study declined to 45 of 399 (11.3%) at week 12. CONCLUSIONS Despite the declining number of participants over time, the combination of social media and smartphone app with sensor integration was a feasible and cost-effective approach for the collection of patient-reported data in rheumatoid arthritis. Integral sensors within smartphones can be harnessed to provide novel end points, and the novel wrist range of movement test warrants further clinical validation.